Background: A program for the prevention of major hemoglobinopathies was initiated in 2008 in the Kurdistan region of Iraq. This study reports on the achievements and challenges of the program. Methods: A total of 102,554 individuals (51,277 couples) visiting a premarital center between 2008 and 2012 were screened for carrier status of hemoglobinopathies, and at-risk couples were counseled. Results: A total of 223 (4.3/1,000) couples were identified and counseled as high-risk couples. Available data on 198 high-risk couples indicated that 90.4% proceeded with their marriage plans, and 15% of these married couples decided to have prenatal diagnosis (PND) in subsequent pregnancies with the identification of 8 affected fetuses; all were terminated as chosen by the parents. Thirty affected births were recorded among the high-risk couples. The premarital program managed to reduce the affected birth rate of major hemoglobinopathies by 21.1%. Of the 136 affected babies born during the study period, 77.9% were born to couples married prior to the start of the program, while 22.1% were born to couples identified as having a high risk. The main reason for not taking the option of PND was unaffordable costs. Conclusions: Financial support would have increased opting for PND by high-risk couples. Further reduction in affected birth rates could be achieved by including parallel antenatal screening programs to cover those married before the initiation of the premarital program and improving the public health education and counseling programs.

Keywords:
Hemoglobinopathies, Iraq, Premarital screening, Prenatal diagnosis
1.
Hamamy H, Al-Allawi N: Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet 2013;4:147-167.
2.
Bain BJ: Hemoglobinopathies Diagnosis, ed 1, Oxford, Blackwell Scientific Publication, 2001.
3.
Yahya HI, Khalel KJ, Al-Allawi NAS, Hilmi F: Thalassaemia genes in Baghdad, Iraq. East Mediterr Health J 1996;2:315-319.
4.
Hassan MK, Taha JY, Al-Noama LM, Widad NM, Jasim SN: Frequency of hemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra. East Mediterr Health J 2003;9:1-8.
5.
Al-Allawi NA, Al-Dousky AA: Frequency of haemoglobinopathies at premarital health screening in Dohuk, Iraq: implications for a regional prevention programme. East Mediterr Health J 2010;16:381-385.
6.
Alkasab FM, Al-Alusi FA, Adnani MS, Alkafajei AM, Al-Shakerchi NH, Noori SF: The prevalence of sickle cell disease in Abu Al-Khasib District of Southern Iraq. J Trop Med Hyg 1981;84:77-80.
7.
Al-Allawi NA, Jalal SD, Nerwey FF, Al-Sayan GOO, Al-Zebari SMS, Alshingaly AA, Markous RD, Jubrael JMS, Hamamy H: Sickle cell disease in the Kurdish population of northern Iraq. Hemoglobin 2012;36:333-342.
8.
Tadmouri GO, Nair P, Obeid T, Al Ali MT, Al Khaja N, Hamamy HA: Consanguinity and reproductive health among Arabs. Reprod Health 2009;6:17.
9.
Jalal SD, Al-Allawi NA, Faraj AH, Ahmed NH: Prevalence of hemoglobinopathies in Sulaimani-Iraq. Dohuk Med J 2008;2:71-79.
10.
Al-Allawi NAS, Jubrael J, Hughson M: Molecular characterization of β-thalassemia in the Dohuk region of Iraq. Hemoglobin 2006;30:479-486.
11.
Al-Allawi NA, Hassan KM, Sheikha AK, Nerweiy FF, Dawood RS, Jubrael J: Beta-thalassemia mutations among transfusion dependent thalassemia major patients in northern Iraq. Mol Biol Int 2010;2010:479282.
12.
Wild BJ, Bain BJ: Investigation of abnormal haemoglobins and thalassaemia; in Bain BJ, Bates I, Laffan MA, Lewis SM (eds): Dacie and Lewis Practical Haematology. Philadelphia, Churchil Livingstone Elsevier, 2012, pp 301-332.
13.
Najmabadi H, Ghamari A, Sahebjam F, Kariminejad R, Hadavi V, Khatibi T, Samavat A, Mehdipour E, Modell B, Kariminejad MH: Fourteen-year experience of prenatal diagnosis of thalassemia in Iran. Community Genet 2006;9:93-97.
14.
Alswaidi FM, O'Brien SJ: Premarital screening programmes for haemaoglobinopathies, HIV, and hepatitis viruses: review and factors affecting success. J Med Screen 2009;16:22-28.
15.
World Health Organization: Proposed international guidelines on ethical issues in medical genetics and genetic services. 1998. http://whqlibdoc.who.int/hq/1998/WHO_HGN_GL_ETH_98.1.pdf.
16.
Hamamy H, Bittles AH: Genetic clinics in Arab communities meeting individuals, family and community needs. Public Health Genomics 2009;12:30-40.
17.
Al-Allawi NAS, Jalal SD, Ahmed NH, Faraj AH, Shalli A, Hamamy H: The first five years of a preventive programme for haemoglobinopathies in northeastern Iraq. J Med Screen 2013;20:171-176.
18.
Samavat A, Modell B: Iranian national thalassemia screening programme. BMJ 2004;329:1134-1137.
19.
Tosun F, Bilgin A, Kizilok A, Arpaci A, Yuregir GT: Five-year evaluation of premarital screening program for Hemoglobinopathies in the province of Mersin, Turkey. Turk J Hematol 2006;23:84-89.
20.
Memish ZA, Saeedi MY: Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and β-thalassemia in Saudi Arabia. Ann Saudi Med 2011;31:229-235.
21.
Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ: Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med 2007;9:372-377.
22.
Al-Sulaiman A, Saeedi M, Al Suliman A, Owaidah T: Postmarital follow-up survey on high risk patients subjected to premarital screening program in Saudi Arabia. Prenat Diagn 2010;30:478-481.
23.
Zahed L, Bou-Dames J: Acceptance of first-trimester prenatal diagnosis for the haemoglobinopathies in Lebanon. Prenat Diagn 1997;17:423-428.
24.
El-Beshlawy A, El-Shekha A, Momtaz M, Said F, Hamdy M, Osman O, Meshaal S, Gafaar T, Petrou M: Prenatal diagnosis for thalassaemia in Egypt: what changed parents' attitude? Prenat Diagn 2012;32:777-782.
25.
Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, Hashemi A: Premarital screening for β-thalassemia in southern Iran: options for improving the programme. J Med Screen 2007;14:62-66.
26.
Ayesh SK, Al-Sharef WA, Nassar SM, Thawabteh NA, Abu-Libdeh BY: Prenatal diagnosis of beta-thalassemia in the West Bank and Gaza. Saudi Med J 2005;26:1771-1776.
27.
Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB: Carrier screening for β-thalassaemia: a review of international practice. Eur J Hum Genet 2010;18:1077-1083.
28.
Al-Arrayed S, Hafadh N, Amin S, Al-Mukhareq H, Sanad H: Student screening for inherited blood disorders in Bahrain. East Mediterr Health J 2003;9:344-352.
29.
Mitchell JJ, Capua A, Clow C, Scriver CR: Twenty-five year outcome analysis of genetic screening programs for Tay-Sachs and β-thalassemia disease carriers in high schools. Am J Med Genet 1996;59:793-798.
30.
El-Beshlawy A, Youssry I: Prevention of hemoglobinopathies in Egypt. Hemoglobin 2009; 33(suppl 1):S14-S20.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.